IGF-1 Complex Dosing for Preterm IVH Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Preterm infants are highly vulnerable to intraventricular hemorrhage (IVH), particularly those born at low gestational ages, due to their inability to autoregulate blood pressure and flow, leading to fluctuations that can cause brain hemorrhage and death, with existing treatments posing risks and lacking effective preventive measures.
Innovation Solution
Administer a therapeutic amount of IGF-1 and IGF binding protein (such as IGFBP-3) complex within 3 hours of birth at a dose of 200-500 μg/Kg/day for at least 7 days, maintaining plasma levels of IGF-1 between 28 μg/L to 109 μg/L to stabilize blood flow and pressure, reducing the incidence and severity of IVH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional medical interventions (such as saline drip, vasopressors, diuretics) are administered to treat preterm infants, then vital functions can be supported, but the risk of intraventricular hemorrhage (IVH) increases due to the infants' inability to autoregulate blood pressure and flow
Solution Approach 1:
The patent introduces IGF-1 as an intermediary substance that mediates between the administered treatments and the infant's vascular system. IGF-1 enhances the maturity and stability of the vascular endothelium, creating a protective intermediary layer that allows conventional treatments to support vital functions while reducing their harmful effects on the vulnerable brain vasculature of preterm infants
Solution Approach 2:
The patent changes the physiological parameters of the vascular system by administering IGF-1, which promotes vascular maturation and improves autoregulatory capacity. This parameter change (enhanced vascular maturity) allows the infant's blood pressure and flow to be better regulated, reducing the risk of IVH while still permitting necessary medical interventions
2Ease of operation
If preterm infants receive standard care without IGF-1 treatment, then treatment simplicity is maintained, but IVH incidence remains high due to lack of protective mechanisms
Solution Approach 1:
The patent applies preliminary action by administering IGF-1 to preterm infants before they are exposed to the full range of medical interventions that could potentially cause IVH. This preliminary treatment enhances vascular maturity and protective mechanisms in advance, creating a buffer against future harmful effects while maintaining relatively simple treatment protocols
3Object-affected harmful factors
If IGF-1 treatment is administered to preterm infants, then IVH incidence and severity are reduced, but treatment complexity and dosing requirements increase
Solution Approach 1:
The patent manages treatment complexity by establishing specific dosing parameters (200-500 μg/Kg/day) and monitoring targets (plasma IGF-1 levels of 28-109 μg/L). These defined parameters provide clear guidance for administration and monitoring, making the treatment protocol manageable despite the added complexity of IGF-1 therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment significantly reduces IVH incidence by over 50% and severity, stabilizes vital functions, and minimizes the need for vasopressors and diuretics, improving respiratory parameters, with a mortality benefit and reduced risk of complications like GMH and PVH.
Implementation Method 1
IGF-1/IGFBP-3 activates the IGF-1 receptor (IGF-1R) and downstream signalling pathway at the CP in the immature brain of the preterm rabbit pup
Implementation Method 2
systemic insulin-like growth factor 1 (IGF-1) can bind to, and translocate through, the choroid plexus (CP) into cerebrospinal fluid
Data Source
AI summary
The present disclosure relates to treatment of subpopulation of neonates for reducing the risk of IVH and/or severe IVH, such as grade 3 or 4 IVH by administering a therapeutic amount of a composition comprising IGF-1 and an IGF binding protein (such as IGFBP-3), for example as a complex, at a dose of 200-500 μg/Kg/day. In a further aspect there is provided stabilisation of vital functions when hyperosmolarity occurs and/or protection from circulatory collapse.